Pyszczymuka Greg's most recent trade in Aytu BioPharma Inc was a trade of 209 Common Shares done . Disclosure was reported to the exchange on March 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 209 | 23,602 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 209 | 0 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 208 | 23,393 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 208 | 209 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2024 | 7,000 | 7,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 209 | 23,185 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 209 | 417 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 208 | 22,976 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 208 | 626 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 208 | 22,768 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 208 | 834 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Pyszczymuka Greg | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 209 | 22,560 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 209 | 1,042 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2023 | 208 | 1,251 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2023 | 208 | 22,351 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 7,000 | 7,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 208 | 22,143 (0%) | 0% | - | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 208 | 1,459 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commerical Officer | Purchase of securities on an exchange or from another person at price $ 1.87 per share. | 16 Jun 2023 | 12,000 | 21,935 (0%) | 0% | 1.9 | 22,428 | Common Shares |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2023 | 833 | 1,667 | - | - | Restricted Stock Units | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2023 | 833 | 9,935 (0%) | 0% | 0 | Common Shares | |
| Aytu BioPharma Inc | Greg Pyszczymuka | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 0.24 per share. | 19 Dec 2022 | 100,000 | 182,056 (0%) | 0% | 0.2 | 24,480 | Common Stock |